CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM...
Early Phase 1
Chicago, Illinois, United States and 4 other locations
This is an open-label, monotherapy study of pemigatinib in participants with recurrent glioblastoma (GBM) or other recurrent glioma...
Phase 2
Chicago, Illinois, United States and 80 other locations
are also impermeable to the passage of therapeutic molecules from the blood to the brain. The development of effective treatments against glioblastoma...
Phase 3
Chicago, Illinois, United States and 22 other locations
To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM...
Chicago, Illinois, United States and 132 other locations
receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expr...
Phase 1, Phase 2
Chicago, Illinois, United States and 24 other locations
Paclitaxel is among the most active agents against glioblastoma in preclinical models. However, its clinical use has been hampered by the bl...
Phase 1, Phase 2
Chicago, Illinois, United States
This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy o...
Phase 1, Phase 2
Warrenville, Illinois, United States and 10 other locations
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an...
Phase 1, Phase 2
Chicago, Illinois, United States and 18 other locations
progression-free survival (PFS) of patients with newly diagnosed glioblastoma multiforme (GBM) can be improved by the addition of i...
Phase 3
Maywood, Illinois, United States and 18 other locations
This is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study. Patients with GBM after failure of standard firs...
Phase 2
Chicago, Illinois, United States and 47 other locations
Clinical trials
Research sites
Resources
Legal